Genespire raises €46.6 million (~$52 million) in a Series B round to advance its first pediatric in-vivo gene therapy into the clinic

da Harry Fowler | Set 25, 2024 | Notizie

Genespire Presents Positive Preclinical Proof of Concept Data at the ASGCT Annual Meeting

da Harry Fowler | Mag 9, 2024 | Notizie

Genespire Strengthens Management Team with Two Key Appointments

da Harry Fowler | Apr 5, 2021 | Notizie

Genespire appoints Jörn Aldag as Chairman of the Board of Directors

da Harry Fowler | Lug 2, 2020 | Notizie

Genespire and the San Raffaele Telethon Institute for Gene Therapyannounce publication in Nature Biotechnology on enhanced gene editingtechnique in hematopoietic stem cells

da Harry Fowler | Giu 2, 2020 | Notizie